Drug intelligence / Profile preview

BMTP-11

Development stage: Phase 1
Lead developer: University of Texas MD Anderson Cancer Center
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Modified Peptides → Peptides
Administration: Intravenous

Overview

BMTP-11 is a tumor-targeting peptidomimetic drug designed to target the interleukin-11 receptor alpha (IL-11Rα). It consists of a functional IL-11Rα-binding peptide (CGRRAGGSC) fused to an apoptosis-inducing peptidomimetic D(KLAKLAK)2. This design enables selective targeting of cancer cells expressing IL-11Rα, inducing apoptosis in these cells. BMTP-11 has shown efficacy in preclinical models of osteosarcoma and prostate cancer with bone metastases, demonstrating ability to inhibit tumor growth and reduce metastatic spread.

Other names: IL-11Ralpha targeted proapoptotic peptideIL11Ralpha targeted proapoptotic peptideIL 11Ralpha targeted proapoptotic peptide

Targets

IL11RA (Interleukin-11 receptor subunit alpha)

Beyond the preview

Go deeper on BMTP-11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMTP-11.

Explore the full profile